The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan

Tzu Hao Li, Hsien Tzung Liao, Yi Fan Huang, Yu Chuan Shen, Yao Chang Chiu, Wei Sheng Chen, Ming Han Chen, Chang Youh Tsai, Deh Ming Chang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.

Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusAccepted/In press - Feb 4 2017
Externally publishedYes

Fingerprint

Psoriatic Arthritis
Taiwan
Physicians
Antirheumatic Agents
Arthritis
Biological Therapy
Rheumatoid Factor
Diagnostic Imaging
Therapeutics
Nails
Biological Products
Observational Studies
Prescriptions
Patient Care
Cross-Sectional Studies
Joints
Interviews
Safety
Skin

Keywords

  • Anti-tumor necrosis factor
  • Biologic DMARDs
  • Multidisciplinary team-care
  • Psoriatic arthritis
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The current status and unmet needs in the management of psoriatic arthritis : Viewpoint from physicians in Taiwan. / Li, Tzu Hao; Liao, Hsien Tzung; Huang, Yi Fan; Shen, Yu Chuan; Chiu, Yao Chang; Chen, Wei Sheng; Chen, Ming Han; Tsai, Chang Youh; Chang, Deh Ming.

In: Journal of the Formosan Medical Association, 04.02.2017.

Research output: Contribution to journalArticle

Li, Tzu Hao ; Liao, Hsien Tzung ; Huang, Yi Fan ; Shen, Yu Chuan ; Chiu, Yao Chang ; Chen, Wei Sheng ; Chen, Ming Han ; Tsai, Chang Youh ; Chang, Deh Ming. / The current status and unmet needs in the management of psoriatic arthritis : Viewpoint from physicians in Taiwan. In: Journal of the Formosan Medical Association. 2017.
@article{d95ebfd63019414da10cdb10ba701d69,
title = "The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan",
abstract = "Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.",
keywords = "Anti-tumor necrosis factor, Biologic DMARDs, Multidisciplinary team-care, Psoriatic arthritis, Treatment",
author = "Li, {Tzu Hao} and Liao, {Hsien Tzung} and Huang, {Yi Fan} and Shen, {Yu Chuan} and Chiu, {Yao Chang} and Chen, {Wei Sheng} and Chen, {Ming Han} and Tsai, {Chang Youh} and Chang, {Deh Ming}",
year = "2017",
month = "2",
day = "4",
doi = "10.1016/j.jfma.2017.05.001",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - The current status and unmet needs in the management of psoriatic arthritis

T2 - Viewpoint from physicians in Taiwan

AU - Li, Tzu Hao

AU - Liao, Hsien Tzung

AU - Huang, Yi Fan

AU - Shen, Yu Chuan

AU - Chiu, Yao Chang

AU - Chen, Wei Sheng

AU - Chen, Ming Han

AU - Tsai, Chang Youh

AU - Chang, Deh Ming

PY - 2017/2/4

Y1 - 2017/2/4

N2 - Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.

AB - Background/Purpose: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. Methods: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. Results: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history. More dermatologists established the diagnosis when psoriatic patients with arthritis didn't present with rheumatoid factors (p < 0.05). For milder arthritis, physicians tended to prescribe etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs). The efficacy, safety, retention rate, and non-parenteral administration are the major concerns of physicians which are also the primary unmet needs in the current management of PsA. Conclusion: This survey showed the status quo in Taiwan of the clinical management for PsA including diagnostic difficulties, therapeutic consideration, rationales for biologic DMARDs selection and unmet needs in treatment. It has indicated that interdisciplinary collaboration may further improve the quality for PsA care. These results may help establish new strategy to develop next generation biologics.

KW - Anti-tumor necrosis factor

KW - Biologic DMARDs

KW - Multidisciplinary team-care

KW - Psoriatic arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85019959236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019959236&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2017.05.001

DO - 10.1016/j.jfma.2017.05.001

M3 - Article

AN - SCOPUS:85019959236

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -